Pharmaceutical News and Articles

Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors

BOTHELL, Wash. May 30, 2026 Immunome, Inc. (Nasdaq IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer thera

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass. June 1, 2026, 07 00 (CEST) UCB (Euronext Brussels UCB) and Biogen Inc. (Nasdaq BIIB) today announced that The Lancet, a w

NIH Research Clears Way for Study of Experimental Treatment for Opioid Use Disorder

The National Institutes of Health (NIH) today announced that its Investigational New Drug (IND) application for mitragynine, the primary psychoactive compound f

FDA Approves Xocova (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure

MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

FDA Approves Zaynich (cefepime and zidebactam) for the Treatment of Complicated Urinary Tract Infections

ASCO: Intismeran Plus Pembrolizumab Ups RFS, DMFS in High-Risk Melanoma

For patients with resected high-risk melanoma, intismeran plus pembrolizumab offers clinically meaningful improvements in recurrence-free survival (RFS) and dis

ASCO: Fasting Before and After Chemo May Up Efficacy in Serous Ovarian Cancer

For women with advanced high-grade serous ovarian cancer (OC), short-term fasting (STF) may enhance the efficacy of chemotherapy, according to a study presented

Some Sedatives Tied to Better Long-Term Neurocognitive Function in Critically Ill Children

Most children who survive a critical illness requiring sedation have IQ scores within the normal range five years later, according to a study published online M

Ocrelizumab Superior for Delaying Disability Progression in Primary Progressive MS

For patients with primary progressive multiple sclerosis (PPMS), ocrelizumab is superior for delaying disability progression, according to a study published in